ResearcherUniversity of PalermoNo recent work listed
Daniele Fanale
Matched on ORCID iD 0000-0001-7668-737X; OpenAlex author ID A5056636166. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 5
- Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: l… First author DOI 10.1016/j.esmoop.2021.100235↗
- Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. First author DOI 10.1080/2162402x.2018.1561120↗
- Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.25745↗
- Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susc… Co-author DOI 10.1517/14728222.2014.920324↗
- Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations. Co-author DOI 10.1159/000354737↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Antonio Dello Russo · 4 shared papers, 2013–2021 · strength 0.26
- Paper Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients … DOI 10.1016/j.esmoop.2021.100235↗
- Paper Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcin… DOI 10.1080/2162402x.2018.1561120↗
- Paper Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target in… DOI 10.1517/14728222.2014.920324↗
- Juan Iovanna · 4 shared papers, 2013–2019 · strength 0.25
- Paper Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcin… DOI 10.1080/2162402x.2018.1561120↗
- Paper Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma. DOI 10.18632/oncotarget.25745↗
- Paper Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target in… DOI 10.1517/14728222.2014.920324↗
- Viviana Bazan · 3 shared papers, 2013–2021 · strength 0.17
- Paper Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients … DOI 10.1016/j.esmoop.2021.100235↗
- Paper Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target in… DOI 10.1517/14728222.2014.920324↗
- Paper Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific var… DOI 10.1159/000354737↗
- Marco Bono · 1 shared paper, 2021 · strength 0.10
- Benjamin Bian · 1 shared paper, 2019 · strength 0.09
- Daniel Olive · 1 shared paper, 2019 · strength 0.09
- Nelson Dusetti · 1 shared paper, 2019 · strength 0.09
- Mirna Swayden · 1 shared paper, 2018 · strength 0.09
- Odile Gayet · 1 shared paper, 2018 · strength 0.09
- Jennifer Bintz · 1 shared paper, 2018 · strength 0.09
- Philippe Soubeyran · 1 shared paper, 2018 · strength 0.09
- María Inés Molejon · 1 shared paper, 2018 · strength 0.09
- Giuseppe Cicero · 2 shared papers, 2013–2014 · strength 0.07
- Paper Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target in… DOI 10.1517/14728222.2014.920324↗
- Paper Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific var… DOI 10.1159/000354737↗
- Christian Diego Rolfo · 1 shared paper, 2014 · strength 0.04
- Daniele Santini · 1 shared paper, 2014 · strength 0.04
- Massimo Midiri · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.